华润双鹤可持续发展报告获认可 万得ESG评级提升至A级

Core Insights - The company, China Resources Double Crane (华润双鹤), achieved a significant improvement in its ESG rating, moving from a score of 6.69 to 7.28, and upgraded from "BBB" to "A" in the 2024 Wind ESG rating, reflecting its commitment to sustainable development over the past decade [2] - The Wind ESG rating serves as a platform for companies to showcase their ESG performance, providing crucial decision-making references for investors, and enhancing the company's image in the capital market [2] - The company has published its sustainable development report for 17 consecutive years, establishing itself as a benchmark for ESG performance in the pharmaceutical industry [2] Summary by Sections Story Section - The company emphasizes its dedication to women's health and children's medication development, along with its "zero-medical connection" chronic disease management system [3] - It highlights its selection as a national-level digital workshop and its efforts in distributed photovoltaic projects for carbon reduction, illustrating how ESG principles are integrated into its strategic framework [3] Management Section - The company has restructured its ESG management system with a strategic perspective, adhering to the latest exchange guidelines in its ESG report [3] - It employs a four-dimensional framework: governance, strategy, impact, risk and opportunity management, and indicators and goals, to deepen its understanding of sustainable development [3] - The sustainable development model is built on one goal, three dimensions, three measures, and five guarantees, aiming to become a world-class pharmaceutical company driven by innovation and public trust [3] Action Section - In governance, the company established a "wood" governance structure, systematically clarifying responsibilities, authorizations, systems, and processes [4] - For environmental protection, it has developed a low-carbon management system across its entire supply chain, with 17 out of 22 production bases certified for environmental management [4] - The company has launched several industry-first initiatives, including the market-leading emergency contraceptive "Yuting" and the first pediatric leukemia microtablet, addressing critical healthcare needs [4] Collaboration and Future Vision - The ESG report is a product of cross-departmental collaboration, involving over ten departments and taking six months to complete data collection and indicator calibration [5] - The company envisions a future where sustainable development is deeply integrated into its business strategy, aiming to elevate its social value and respond to contemporary challenges [6] - The journey towards enhanced ESG performance signifies a shift from compliance to value creation, marking the beginning of a new era for the company [6]